

Preliminary Third-quarter 2025 Financial Results

■ Revenue

- Revenue for Q3 '25 exceeded KRW 1 trillion, up +16.3% YoY to KRW 1.026 trillion
- Biologics revenue increased by +18.3% YoY
 - High margin young products recorded a +50.5% YoY increase, with key products such as Remsima SC, Zymfentra and Steqeyma driving overall revenue growth
 - Stoboclo(U.S., July) and Omlyclo(EU, Sep.), both launched in Q3 '25, recorded combined sales of approximately KRW 50 billion, demonstrating successful entry into the market. Growth momentum to strengthen in Q4, supported by prescription ramp-up of young products and upcoming launches(Eydenzelt and Avtozma)
 - **The sales contribution of high-margin young products has steadily increased, leading to margin improvement** [Young Products Sales Ratio : 42%(Q3 '24) → 53%(Q2 '25) → 54%(Q3 '25)]
 - Sales of advanced products declined -5.5% YoY. The decline was limited to Remsima due to a high base effect from temporary supply expansion in 2024, while Truxima and Herzuma recorded significant sales growth
- Non-bio sales declined YoY following the transfer of Takeda's primary care rights, with limited impact on OP

■ Operating Profit

- Q3 '25 OP hit KRW 301 billion, up +44.9% YoY, **marking the first-ever quarterly OP to exceed KRW 300 billion**
- **OPM rebounded to the 30% range**, reflecting accelerated profitability improvement
- **Notably, the COGS ratio returned to the 30% range for the first time since the merger**, as merger-related impacts have normalized [COGS ratio: 48% (Q3 '24) → 43% (Q2 '25) → 39% (Q3 '25)]
 - Structural improvement in COGS continues, driven by high-cost inventory depletion, production transition to TI-versions, completion of R&D amortization and product mix enhancement—with further improvement expected in Q4

[Unit: KRW billion]

		3Q25(P)	3Q24	YoY	2Q25	QoQ	2025 3Q YTD(P)	2024 3Q YTD	YoY
Sales		1,026.0	881.9	16.3%	961.5	6.7%	2,829.4	2,493.6	13.5%
Biologics		958.3	810.0	18.3%	882.8	8.6%	2,608.7	2,235.2	16.7%
Product	Advanced ¹⁾	442.0	467.5	-5.5%	414.8	6.6%	1,277.2	1,445.3	-11.6%
	Young ²⁾	516.3	342.5	50.7%	468.0	10.3%	1,331.5	789.9	68.6%
Non-Biologics		67.7	71.9	-5.8%	78.7	-14.0%	220.7	258.4	-14.6%
Gross Profit		622.7	463.4	34.4%	544.4	14.4%	1,610.0	1,137.9	41.5%
GPM(%)		60.7%	52.5%	8.2%p	56.6%	4.1%p	56.9%	45.6%	11.3%p
Operating Profit		301.0	207.7	44.9%	242.5	24.1%	692.9	295.6	134.4%
OPM(%)		29.3%	23.6%	5.7%p	25.2%	4.1%p	24.5%	11.9%	12.6%p

1) Advanced: Remsima, Truxima, Herzuma

2) Young: Remsima SC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, Omlyclo, Stoboclo&Osenvelt, etc.

The above preliminary financial results are based on the company's internal accounting data and have not been reviewed by an external auditor. They are provided for investors' convenience only and may differ from the final audited results.